Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company headquartered in Tokyo, Japan, and one of the largest pharmaceutical companies in Asia. Founded in 1781 as a traditional medicine business by Chobei Takeda I, the company has evolved over more than two centuries to become a global leader in innovative pharmaceuticals and healthcare solutions. Takeda focuses on four core therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology, with a robust pipeline of over 40 late-stage development programs. The company's flagship products include Entyvio for inflammatory bowel disease, Ninlaro for multiple myeloma, Adcetris for lymphomas, and Vyvanse for ADHD treatment. Following its major acquisition of Shire plc in 2019 for $62 billion, Takeda significantly expanded its rare disease portfolio and global presence, particularly in Western markets. The company operates in over 80 countries and regions worldwide, with major research and development centers in Japan, the United States, Europe, and other key markets. With approximately 50,000 employees globally, Takeda invests heavily in R&D, dedicating around 15% of its revenue to research and development activities. The company is listed on the Tokyo Stock Exchange and is a component of the Nikkei 225 index. Takeda has established strategic partnerships with academic institutions, biotechnology companies, and other pharmaceutical firms to advance cutting-edge therapies, particularly in oncology and rare diseases. The company is committed to improving patient outcomes through innovative medicines while maintaining its core values of integrity, fairness, honesty, and perseverance.